



## Establishment Labs Announces Appointment of Ann Custin and Bryan Slotkin to Board of Directors

July 15, 2021

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Jul. 15, 2021-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced the appointment of Ann Custin and Bryan Slotkin to its Board of Directors, effective immediately.

"We are delighted to have these two very accomplished individuals join the Board of Establishment Labs," said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. "Good governance is essential to our mission of improving women's health. Their unique perspectives will be critical as we continue to reshape and expand our industry by offering differentiated technologies that create value for all stakeholders."

Ms. Custin was most recently with Siemens Healthineers, where she was Board Director and Chief Financial Officer of Siemens Medical Solutions; she retired from the company in December 2019. Ms. Custin previously served as Chief Operating and Financial Officer of Scient'x and President and CEO USA of Draeger Medical Systems.

"Establishment Labs has proven that true innovation coupled with the guiding principle of improving women's health can be transformative," said Ann Custin. "We are bringing a compelling combination to the market, and I am excited to join the Board as we prepare to enter new geographies and launch exciting new products."

Mr. Slotkin is a Partner with PJT Partners, a global advisory-focused investment bank. He is responsible for the firm's global financial sponsor relationships and is a strategic advisor to public and private companies in the real estate, gaming, leisure, consumer, and healthcare sectors. Mr. Slotkin was previously a Managing Director with Goldman Sachs.

"I have been fortunate to know Establishment Labs for many years and to watch the company's growth and maturation into an industry leader," said Bryan Slotkin. "The team has created a tremendous amount of value, but there is still much more to come. I look forward to working with Juan José and the Board as we continue on our mission to positively impact the lives of women around the world."

### About Establishment Labs

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the Motivalmagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company's direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs' product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at [www.establishmentlabs.com](http://www.establishmentlabs.com).

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). You can find many (but not all) of these statements by looking for words such as "approximates," "believes," "expects," "anticipates," "estimates," "intends," "plans," "intends to," "would," "will," "may" or other similar expressions in this press release. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company's performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors that could cause or contribute to these differences include, among others, those risks

and uncertainties discussed in the company's annual report on Form 10-K filed on March 15, 2021, quarterly reports on Form 10-Q, and other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210715005286/en/): <https://www.businesswire.com/news/home/20210715005286/en/>

**Investor/Media Contact:**

Raj Denhoy

415-828-1044

[rdenhoy@establishmentlabs.com](mailto:rdenhoy@establishmentlabs.com)

Source: Establishment Labs Holdings Inc.